Meribank Biotech Co., Ltd
Meribank Biotech Co., Ltd researches, develops, manufactures, and stores mesenchymal stem cells in Taiwan. The company engages in the detection, extraction, cryopreservation, archiving, and storage of umbilical cord blood, placental and umbilical cord mesenchymal stem cells, adult peripheral blood stem cells, and immune cells. It also provides cell cryopreservation services. The company was found… Read more
Meribank Biotech Co., Ltd (4724) - Total Liabilities
Latest total liabilities as of June 2025: NT$1.62 Billion TWD
Based on the latest financial reports, Meribank Biotech Co., Ltd (4724) has total liabilities worth NT$1.62 Billion TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Meribank Biotech Co., Ltd - Total Liabilities Trend (2019–2024)
This chart illustrates how Meribank Biotech Co., Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Meribank Biotech Co., Ltd Competitors by Total Liabilities
The table below lists competitors of Meribank Biotech Co., Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Okong Corporation
KQ:045060
|
Korea | ₩25.00 Billion |
|
Fathom Holdings Inc
NASDAQ:FTHM
|
USA | $39.86 Million |
|
Apollo Food Holdings Bhd
KLSE:6432
|
Malaysia | RM23.53 Million |
|
Black Iron Inc
PINK:BKIRF
|
USA | $4.33 Million |
|
Sukhjit Starch & Chemicals Limited
NSE:SUKHJITS
|
India | ₹6.04 Billion |
|
Modulight Oyj
HE:MODU
|
Finland | €5.98 Million |
|
Jeil Technos Co.Ltd
KQ:038010
|
Korea | ₩39.00 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Meribank Biotech Co., Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.57 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Meribank Biotech Co., Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Meribank Biotech Co., Ltd (2019–2024)
The table below shows the annual total liabilities of Meribank Biotech Co., Ltd from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$1.46 Billion | +274.75% |
| 2023-12-31 | NT$390.81 Million | +4.91% |
| 2022-12-31 | NT$372.53 Million | +3.12% |
| 2021-12-31 | NT$361.27 Million | +4.01% |
| 2020-12-31 | NT$347.34 Million | +34.26% |
| 2019-12-31 | NT$258.71 Million | -- |